Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
9
SYRS Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-15.9%
Day range:
$0.0002 - $0.0101
52-week range:
$0.0001 - $0.2969
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
9.66x
Volume:
4.2K
Avg. volume:
35.7K
1-year change:
-99.89%
Market cap:
$5.4K
Revenue:
$9.9M
EPS (TTM):
-$3.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
-- | -$0.76 | -6.74% | -68.02% | -- |
|
BTAX
Biostax Corp.
|
-- | -- | -- | -- | -- |
|
FNAM
Evolutionary Genomics, Inc.
|
-- | -- | -- | -- | -- |
|
FPMI
FluoroPharma Medical, Inc.
|
-- | -- | -- | -- | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
-- | -- | -- | -- | -- |
|
MTST
MetaStat, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
$0.0002 | -- | $5.4K | -- | $0.00 | 0% | 0.02x |
|
BTAX
Biostax Corp.
|
$0.0001 | -- | $7.9K | -- | $0.00 | 0% | -- |
|
FNAM
Evolutionary Genomics, Inc.
|
$0.0002 | -- | $1.3K | -- | $0.00 | 0% | 0.01x |
|
FPMI
FluoroPharma Medical, Inc.
|
$0.0002 | -- | $6.9K | -- | $0.00 | 0% | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
$0.0000 | -- | $1.2K | -- | $0.00 | 0% | -- |
|
MTST
MetaStat, Inc.
|
$0.0006 | -- | $3.5K | -- | $0.00 | 0% | 0.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
-- | 5.161 | -- | -- |
|
BTAX
Biostax Corp.
|
-- | 5.189 | -- | -- |
|
FNAM
Evolutionary Genomics, Inc.
|
-- | 1.375 | -- | -- |
|
FPMI
FluoroPharma Medical, Inc.
|
-- | -230.293 | -- | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
-- | -1.486 | -- | -- |
|
MTST
MetaStat, Inc.
|
-- | 2,921.124 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SYRS
Syros Pharmaceuticals, Inc.
|
-- | -$26.2M | -- | -- | -- | -$20.7M |
|
BTAX
Biostax Corp.
|
-- | -$300K | -- | -- | -- | -$2.1K |
|
FNAM
Evolutionary Genomics, Inc.
|
-- | -- | -- | -- | -- | -- |
|
FPMI
FluoroPharma Medical, Inc.
|
-- | -- | -- | -- | -- | -- |
|
GSTC
GlobeStar Therapeutics Corp.
|
-- | -$193.4K | -- | -- | -- | -$20.4K |
|
MTST
MetaStat, Inc.
|
-- | -- | -- | -- | -- | -- |
Syros Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns SYRS or BTAX?
Biostax Corp. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat Biostax Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- BTAXBiostax Corp.-- -$0.01 -- -
What do Analysts Say About SYRS or BTAX?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 499900%. On the other hand Biostax Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than Biostax Corp., analysts believe Syros Pharmaceuticals, Inc. is more attractive than Biostax Corp..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 BTAXBiostax Corp.0 0 0 -
Is SYRS or BTAX More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.099, which suggesting that the stock is 9.937% more volatile than S&P 500. In comparison Biostax Corp. has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.633%.
-
Which is a Better Dividend Stock SYRS or BTAX?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biostax Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biostax Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or BTAX?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Biostax Corp. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is lower than Biostax Corp.'s net income of -$428K. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Biostax Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.02x versus -- for Biostax Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.02x -- -- -$6.4M BTAXBiostax Corp.-- -- -- -$428K
-
Which has Higher Returns SYRS or FNAM?
Evolutionary Genomics, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat Evolutionary Genomics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- FNAMEvolutionary Genomics, Inc.-- -- -- -
What do Analysts Say About SYRS or FNAM?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 499900%. On the other hand Evolutionary Genomics, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than Evolutionary Genomics, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than Evolutionary Genomics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 FNAMEvolutionary Genomics, Inc.0 0 0 -
Is SYRS or FNAM More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.099, which suggesting that the stock is 9.937% more volatile than S&P 500. In comparison Evolutionary Genomics, Inc. has a beta of -0.142, suggesting its less volatile than the S&P 500 by 114.231%.
-
Which is a Better Dividend Stock SYRS or FNAM?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evolutionary Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Evolutionary Genomics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or FNAM?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Evolutionary Genomics, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is higher than Evolutionary Genomics, Inc.'s net income of --. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Evolutionary Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.02x versus 0.01x for Evolutionary Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.02x -- -- -$6.4M FNAMEvolutionary Genomics, Inc.0.01x -- -- --
-
Which has Higher Returns SYRS or FPMI?
FluoroPharma Medical, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat FluoroPharma Medical, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- FPMIFluoroPharma Medical, Inc.-- -- -- -
What do Analysts Say About SYRS or FPMI?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 499900%. On the other hand FluoroPharma Medical, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than FluoroPharma Medical, Inc., analysts believe Syros Pharmaceuticals, Inc. is more attractive than FluoroPharma Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 FPMIFluoroPharma Medical, Inc.0 0 0 -
Is SYRS or FPMI More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.099, which suggesting that the stock is 9.937% more volatile than S&P 500. In comparison FluoroPharma Medical, Inc. has a beta of -120.204, suggesting its less volatile than the S&P 500 by 12120.43%.
-
Which is a Better Dividend Stock SYRS or FPMI?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FluoroPharma Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. FluoroPharma Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or FPMI?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than FluoroPharma Medical, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is higher than FluoroPharma Medical, Inc.'s net income of --. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while FluoroPharma Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.02x versus -- for FluoroPharma Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.02x -- -- -$6.4M FPMIFluoroPharma Medical, Inc.-- -- -- --
-
Which has Higher Returns SYRS or GSTC?
GlobeStar Therapeutics Corp. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat GlobeStar Therapeutics Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- GSTCGlobeStar Therapeutics Corp.-- -$0.00 -- -
What do Analysts Say About SYRS or GSTC?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 499900%. On the other hand GlobeStar Therapeutics Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Syros Pharmaceuticals, Inc. has higher upside potential than GlobeStar Therapeutics Corp., analysts believe Syros Pharmaceuticals, Inc. is more attractive than GlobeStar Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 GSTCGlobeStar Therapeutics Corp.0 0 0 -
Is SYRS or GSTC More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.099, which suggesting that the stock is 9.937% more volatile than S&P 500. In comparison GlobeStar Therapeutics Corp. has a beta of 1.660, suggesting its more volatile than the S&P 500 by 65.979%.
-
Which is a Better Dividend Stock SYRS or GSTC?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlobeStar Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. GlobeStar Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or GSTC?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than GlobeStar Therapeutics Corp. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is lower than GlobeStar Therapeutics Corp.'s net income of -$197.7K. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while GlobeStar Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.02x versus -- for GlobeStar Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.02x -- -- -$6.4M GSTCGlobeStar Therapeutics Corp.-- -- -- -$197.7K
-
Which has Higher Returns SYRS or MTST?
MetaStat, Inc. has a net margin of -- compared to Syros Pharmaceuticals, Inc.'s net margin of --. Syros Pharmaceuticals, Inc.'s return on equity of -- beat MetaStat, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SYRSSyros Pharmaceuticals, Inc.-- -$0.16 -- MTSTMetaStat, Inc.-- -- -- -
What do Analysts Say About SYRS or MTST?
Syros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 499900%. On the other hand MetaStat, Inc. has an analysts' consensus of -- which suggests that it could grow by 1833233.33%. Given that MetaStat, Inc. has higher upside potential than Syros Pharmaceuticals, Inc., analysts believe MetaStat, Inc. is more attractive than Syros Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SYRSSyros Pharmaceuticals, Inc.0 3 0 MTSTMetaStat, Inc.0 0 0 -
Is SYRS or MTST More Risky?
Syros Pharmaceuticals, Inc. has a beta of 1.099, which suggesting that the stock is 9.937% more volatile than S&P 500. In comparison MetaStat, Inc. has a beta of 304.756, suggesting its more volatile than the S&P 500 by 30375.643%.
-
Which is a Better Dividend Stock SYRS or MTST?
Syros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MetaStat, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Syros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MetaStat, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SYRS or MTST?
Syros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than MetaStat, Inc. quarterly revenues of --. Syros Pharmaceuticals, Inc.'s net income of -$6.4M is higher than MetaStat, Inc.'s net income of --. Notably, Syros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while MetaStat, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Syros Pharmaceuticals, Inc. is 0.02x versus 0.14x for MetaStat, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SYRSSyros Pharmaceuticals, Inc.0.02x -- -- -$6.4M MTSTMetaStat, Inc.0.14x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
